Corline announces positive 5-year results for Renaparin
The study shows good kidney function after 60 months and indicates better results compared to untreated paired kidneys.
See the latest news and media coverage for Corline. We track all announcements, press releases, and industry mentions in real time, all in one place.
Antithrombotic and antiinflammatory surface coating solutions provider
corline.seLast updated
In short: Corline reported positive 5-year results for Renaparin and secured a 2 billion SEK licensing deal with Kardium for its CHS technology.
The study shows good kidney function after 60 months and indicates better results compared to untreated paired kidneys.
Net sales increased to 4,291 KSEK. The result after financial net was -2,501 KSEK. Issue and loan from Kardium provided 18.5 MSEK.
The annual report for the accounting year 2025 is made available on the company's website www.corline.se.
The annual general meeting is held on 12 May 2026 in Uppsala with proposals regarding board election, fees and share issue authorization.
Corline Biomedical AB will release its next earnings report on Aug 21, 2026.
The Corline Biomedical AB EPS (TTM) is -0.57.
U.S. President Donald Trump is injecting nearly $9 billion into Intel in exchange for a 9.9% equity stake. But the money - which the struggling...
Asian stock markets fought to hold their footing on Tuesday after a furious flight from U.S. assets undermined Wall Street and the dollar, while concerns...
Track Corline and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.